2024
52875 Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials, and contextualization with a US cohort of patients with AA
Sicco K, Soung J, Strober B, Irvine A, Wajsbrot D, Gromek K, Wolk R, Barnes D, Takiya L. 52875 Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials, and contextualization with a US cohort of patients with AA. Journal Of The American Academy Of Dermatology 2024, 91: ab55. DOI: 10.1016/j.jaad.2024.07.228.Peer-Reviewed Original Research
2021
Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials
Reich K, Blauvelt A, Lebwohl M, Papp K, Rich P, Strober B, De Cuyper D, Madden C, Peterson L, Vanvoorden V, Warren R. Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials. SKIN The Journal Of Cutaneous Medicine 2021, 5: s21. DOI: 10.25251/skin.5.supp.21.Peer-Reviewed Original Research